Inequity in access to vaccines: the failure of the global response to the COVID-19 pandemic

https://doi.org/10.18294/sc.2022.4190

Published 1 October 2022 Open Access


Antonio Ugalde Emeritus Professor, Department of Sociology, University of Texas-Austin, USA. President, Salud y Fármacos. El Paso, Texas, USA. image/svg+xml , Fernando Hellmann Department of Public Health, Universidade Federal de Santa Catarina, Brazil. Visiting Professor, School of Public Health, Université de Montréal, Canada. image/svg+xml , Núria Homedes Adjunct Professor, Georgetown University. Executive Director, Salud y Fármacos. El Paso, Texas, USA. image/svg+xml



Abstract views
1013
Metrics Loading ...

Crossref
Scopus
Google Scholar
Europe PMC

Keywords:

Vaccines, COVID-19, Global Health, Delivery of Health Care

Abstract


This article summarizes the strategies used to rapidly develop COVID-19 vaccines and distribute them globally, with an emphasis on vaccines developed in western nations. It is based on interviews and information gathered regarding the response to the pandemic, both from international organizations and official documents from Brazil, Argentina, Colombia, Peru, and Mexico. While vaccine development has been hailed as successful, their global distribution has been highly unequal. We look at how the pandemic succeeded in mobilizing large quantities of government resources, and how citizens volunteered their bodies so that clinical trials could be completed quickly. However, patents prevented the expansion of manufacturing capacity, and the governments of a few wealthy countries prioritized the protection – and in some cases overprotection – of their citizens at the expense of protecting the rest of world’s population. Among the major beneficiaries of the global response to the pandemic are the leading vaccine companies, their executives, and investors. The article concludes with some of the lessons learned in this process.


References


1. Ball P. The lightning-fast quest for COVID vaccines - and what it means for other diseases. Nature. 2021;589:16-18.

2. Prüβ BM. Current State of the First COVID-19 Vaccines. Vaccines. 2021;9:1-12.

3. Lemire J, Superville D, Perrone M. White House threatens FDA chief’s job over vaccine approval. AP News [Internet]. 2020 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/3euf4j43.

4. Colarossi N. How long it took to develop 12 other vaccines in history. Business Insider [Internet]. 2020 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/3mkk4k4t.

5. Frazier K, Neeley T. Merck CEO Ken Frazier discusses a COVID cure, racism, and why leaders need to walk the talk. Harvard Working Knowledge [Internet]. 2020 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/yckes6ra.

6. Ledford H. What the Moderna-NIH COVID vaccine patent fight means for research. Nature. 2021;600:200-201.

7. Janssen Biotech, Vaccines and Related Biological Products Advisory Committee. COVID-19 Vaccine Ad26.COV2.S. VAC31518 (JNJ-78436735): Sponsor briefing document [Internet]. 26 Feb 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/y5ewjzay.

8. Salud y Fármacos. Estudio de la implementación del ensayo clínico ENSEMBLE en seis países de América Latina. En prensa, 2022.

9. Outlook Web Desk. Zydus Cadila’s 3-Dose Covid Vaccine ZyCoV-D gets Drugs Controller General of India DCGI’s approval for Emergency Use Authorization EUA. Outlook [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/35xp5e2y.

10. Pulla P. Scientists criticize ‘rushed’ approval of Indian COVID-19 vaccine without efficacy data. Science. 2021.

11. Nagarajan R. “I have no clue. I have never seen anything like it”. The Times of India [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/ytft5xjc.

12. Texas Children’s Hospital. Texas Children’s Hospital and Baylor College of Medicine COVID-19 Vaccine Technology Secures Emergency Use Authorization in India. Texas Children’s Hospital [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/y85uppj4.

13. Mguni M. Botswana approves Corbevax Covid vaccine, plans local output. Bloomberg News [Internet]. 2022 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/2s3v5bb7.

14. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Final analysis of efficacy and safety of single-dose Ad26.COV2.S. New England Journal of Medicine. 2022;386:847-860.

15. Coetzee N. The future of clinical trial recruitment. PharmaLive [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/44a77yd2.

16. Ramakumar R. Whose intellectual property is Bharat Biotech’s publicly funded Covaxin? India deserves an answer. Scroll.In [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/bdh2uyep.

17. Safi M. Oxford/AstraZeneca Covid vaccine research ‘was 97% publicly funded’. The Guardian [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/4yyakef7.

18. Ahmed A. India to fund capacity boost at Serum Institute, Bharat Biotech as vaccines run short. Reuters [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/375erzw6.

19. Jarach CM, Turone F. Soberana y Abdala: vacunas anti-COVID-19 desarrolladas en Cuba. Medscape [Internet]. 2022 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/3jcztcb6.

20. Banco Centroamericano de Integración Económica. BCIE aprueba primera operación a Cuba por €46.7 millones en apoyo al combate de la COVID-19. Banco Centroamericano de Integración Económica [Internet]. 2022 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/57efkutp.

21. Burleigh N. How the Covid-19 vaccine injected billions into Big Pharma-and made its executives very rich. Forbes [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/7farr439.

22. Frank RG, Dach L, Lurie N. It was the government that produced COVID-19 vaccine success. Health Affairs. 2021.

23. Health and Human Services Administration. Biden administration announces historic manufacturing collaboration between Merck and Johnson & Johnson to expand production of COVID-19 vaccines [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/hfewrv4y.

24. Public Citizen. Declaración: In vaccine patent fight, NIH shows a modicum of verve at last. Public Citizen [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/2p97z6h5.

25. Erman M. U.S. to pay $1 billion for 100 million doses of Johnson & Johnson’s COVID-19 vaccine candidate. Reuters [Internet]. 2020 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/uhs489sk.

26. Higgins-Dunn N. Trump says U.S. has reached deal with Moderna for 100 million doses of coronavirus vaccine. CNBC [Internet]. 2020 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/3mujtmru.

27. Lupkin S. U.S. Government May Find It Hard To Get More Doses Of Pfizer’s COVID-19 Vaccine. NPR [Internet]. 2020 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/4tu2re3n.

28. Gallagher J. Coronavirus vaccine: UK government signs deals for 90 million doses. BBC News [Internet]. 2020 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/psrj6sja.

29. Infobae. La Unión Europea declaró que está lista para hablar sobre la liberación de patentes de vacunas contra el COVID-19. Infobae [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/yjavapxr.

30. Ahmed SH, Waseem S, Shaikh TG, Qadir NA, Siddiqui SA, Ullah I, et al. SARS-CoV-2 vaccine-associated-tinnitus: A review. Annals of Medicine and Surgery. 2022;75:103293.

31. Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. New England Journal of Medicine. 2021;385:e83.

32. Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwels KB, et al. The impact of SARS-CoV-2 vaccination on Alpha & Delta variant transmission. medRxiv. 2021.

33. Franco-Paredes C. Transmissibility of SARS-CoV-2 among fully vaccinated individuals. The Lancet Infectious Diseases. 2022;22:16.

34. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning immunity after the BNT162b2 vaccine in Israel. New England Journal of Medicine. 2021;385:e85.

35. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. New England Journal of Medicine. 2021;385:e84.

36. Singanayagam A, Hakki S, Dunning J, Madon KJ, Crone MA, Koycheva A, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. The Lancet Infectious Diseases. 2022;22:183-195.

37. Kissler SM, Fauver JR, Mack C, Tai CG, Breban MI, Watkins AE, et al. Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated persons. New England Journal of Medicine. 2021;385:2489-2491.

38. Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. The Lancet. 2022;399:814-823.

39. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry: E9 Statistical Principles for Clinical [Internet]. 1998 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/mresc4s2.

40. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Statistical Principles for Clinical Trials E9 [Internet]. 5 feb 1998 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/2ze7u4wa.

41. Rizvi Z. El poder de Pfizer. Public Citizen [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/2p87fdv4.

42. Davies M, Furneaux R, Langlois J, Ruiz I. ‘Held to ransom’: Pfizer demands governments gamble with state assets to secure vaccine deal. The Bureau of Investigative Journalism [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/2spc92tp.

43. Colombia, Sistema Nacional de Gestión del Riesgo de Desastres, Unidad Nacional para la Gestión del Riesgo de Desastres. Respuesta traslado por competencia Radicado No. 202124000361401 del Ministerio de Salud y Protección Social numeral Radicado UNGRD No. 2021ER02300. Bogotá: UNGRD; 2021.

44. Bermudez L, Bermudez J. Covid-19: os desafios do acesso a tecnologias no mundo globalizado. Centro de Estudios Estratégicos Fiocruz [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/3sfx9vmv.

45. Wemos. Review of initiatives for access to Covid-19 innovations. [Internet]. 2022 [citado 2 mar 2022]. Disponible en: https://covid19response.org.

46. World Health Organization. WHO COVID-19 Technology Access Pool [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/5n7x4b4d.

47. Pamuk H, Lewis S. U.S. brokers J&J-COVAX deal to send vaccines to conflict zones -Blinken. Reuters [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/2zxmx3mr.

48. Romo V, Henley S. CDC narrows use of J&J vaccine due to concerns about rare blood clots. NPR [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/3ymfac9a.

49. Worley W. WHO and Costa Rica launch COVID-19 technology access pool. Devex [Internet]. 2020 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/4r9x7vm7.

50. Lang K. Molnupiravir vs. COVID-19: Has it lived up to the early hype? MedicalNewsToday [Internet]. 2022 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/428amz6c.

51. Onda Cero, La farmacéutica Merck facilita la fabricación de su antiviral contra la Covid. Onda Cero [Internet]. 2022 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/yck7afeb.

52. Pfizer. Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants. Pfizer [Internet]. 2022 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/bddwpajn.

53. Ravelo JL. G-20 panel call: $75B for pandemic prevention and preparedness. Devex [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/mrxm6nx3.

54. Mookim M. The world loses under Bill Gates’ vaccine colonialism. Wired [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/5cffryuy.

55. Infosalus. MPP, OMS, AFRIGEN, BIOVAC, SAMRC y África CDC acuerdan establecer el centro de transferencia de tecnología en Sudáfrica. Infosalus [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/3k4pz2r8.

56. Our World in Data. Coronavirus (COVID-19) Vaccinations [Internet]. 2022 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/35wbw35r.

57. Institute for Health Metrics and Evaluation. COVID-19 vaccine efficacy summary [Internet]. 2022 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/4mr692vj.

58. World Health Organization. WHO SAGE roadmap for prioritizing use of COVID-19 vaccines [Internet]. 2022 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/4pyc57sj.

59. Love J. KEI and Public Citizen letter to Congress regarding Costa Rica proposal for WHO COVID-19 pool of rights in technology and data. Knowledge Ecology International [Internet]. 2020 [citado 2 mar 2022]. Disponible en: https://www.keionline.org/32649.

60. Médecins Sans Frontières. MSF responds to another misleading attempt by EU to undermine TRIPS Waiver [Internet]. 2020 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/mdmkjvn7.

61. Walsh K, Wallace A, Pavis M, Olszowy N, Griffin J, Hawkins N. Intellectual property rights and access in crisis. IIC - International Review of Intellectual Property and Competition Law. 2021;52:379-416.

62. United Nations. Universal Declaration of Human Rights [Internet]. 1948 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/3xmfpm7x.

63. World Health Organization. Constitution of the World Health Organization [Internet]. 1946 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/mr32dwzd.

64. World Trade Organization. WTO, WCO chiefs pledge joint efforts to facilitate trade in essential goods [Internet]. 2020 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/eeybd4z7.

65. World Trade Organization. IMF and WTO heads call for lifting trade restrictions on medical supplies and food [Internet]. 2020 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/589kucsp.

66. Third World Network. Two-thirds of WTO members issue call for a TRIPS waiver. [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/2p85997j.

67. Office of the United States Trade Representative. Statement from Ambassador Katherine Tai on the Covid-19 Trips Waiver [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/423szbky.

68. Hoen ET, Boulet P. The EU proposed Covid waivers of certain TRIPS rules are mostly meaningless. Medicines Law & Policy [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/8tvt4d4n.

69. Moens B, Furlong A. European Parliament backs patent waiver for coronavirus vaccines. Politico [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/yckwe2dd.

70. Europa Press. Von der Leyen responde a Biden: Suspender las patentes no resolverá el problema inmediato, hay que exportar [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/mryn8suh.

71. Bonadio E, Chandler DMC. Propiedad intelectual y medicamentos para el coronavirus: ¿alcanza con una exención de la Organización Mundial del Comercio? Chequeado [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/yckfntda.

72. Human Rights Watch. Seven reasons the EU is wrong to oppose the TRIPS waiver [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/ye7fs5t7.

73. Marans D. New European vaccine proposal offers limited help to developing countries. Huffpost [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/3z4xrpt8.

74. Abbas MZ. Canada’s political choices restrain vaccine equity: The Bolivia-biolyse case. The South Centre [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/mreawf6t.

75. Abinader LG. Bolivia seeks to import COVID-19 vaccines from Biolyse, if Canada grants them a compulsory license. Knowledge Ecology International [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://www.keionline.org/36119.

76. Reuters Covid-19 Tracker. Bolivia [Internet]. 2022 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/2p93ke3z.

77. France 24. Pfizer’s 2021 profits doubled to $22 bn on strong Covid vaccine sales [Internet]. 2022 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/yv7cesvt.

78. Kimball S. Pfizer CEO Albert Bourla received $24.3 million in total compensation for 2021. CNBC [Internet]. 2022 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/mrhtdnwp.

79. Isidore C. Pfizer revenue and profits soar on its Covid vaccine business. CNN [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/yc99da8y.

80. Kimball S. Pfizer expects $54 billion in 2022 sales on Covid vaccine and treatment pill. CNBC [Internet]. 2022 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/4rb7u28t.

81. Baker S, Silver V. Pfizer fights to control secret of $ 36 billion vaccine recipe. Bloomberg [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/2es89jj6.

82. Epstein J. Pfizer expects to make nearly as much revenue just from COVID-19 vaccines in 2021 as it earned in all of 2020. Business Insiderr [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/yx7mrued.

83. Meyer D. AstraZeneca shifts away from nonprofit model for its COVID-19 vaccine, except when selling to poor countries. Fortune [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/cccet6fw.

84. Kansteiner F. AstraZeneca CEO snared more than $18M last year as his company worked through highs and lows of vaccine launch. Fierce Pharma [Internet]. 2022 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/ykdnhnv9.

85. Johnston M. How Moderna makes money. Investopedia [Internet]. 2022 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/44vdh4d3.

86. Moderna. Moderna reports fourth quarter and fiscal year 2021 financial results and provides business updates [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/mryjs8be.

87. Keown A. Moderna CEO’s Salary Spikes while the median employee’s falls. Biospace [Internet]. 2022 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/muayfu97.

88. Munira SL, Hendriks JT, Atmosukarto II, Friede MH, Carter LM, Butler JRG, Clements ACA. A cost analysis of producing vaccines in developing countries. Vaccine. 2019;37:1245-1251.

89. Marriott A, Maitlandott A. The great vaccine robbery: Pharmaceutical corporations charge excessive prices for COVID-19 vaccines while rich countries block faster and cheaper route to global vaccination. The People’s Vaccine [Internet]. 2021 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/2p8sssuu.

90. Cullinan K. With COVID vaccine supply outstripping vaccination rates, pharma giants question pursuit of IP waiver. Health Policy Watch [Internet]. 2022 [citado 2 mar 2022]. Disponible en: https://tinyurl.com/2p8z662r.